Robert S. Kerbel - Publications

Affiliations: 
University of Toronto, Toronto, ON, Canada 
Area:
Medical Biophysics, Cell Biology

106 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, ... ... Kerbel RS, et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. PMID 29766399 DOI: 10.1007/s10456-018-9613-x  0.36
2016 Shaked Y, Pham E, Hariharan S, Magidey K, Beyar-Katz O, Xu P, Man S, Wu F, Miller V, Andrews DW, Kerbel RS. Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy. Cancer Research. PMID 27569209 DOI: 10.1158/0008-5472.CAN-16-0136  0.56
2016 Pham E, Yin M, Peters CG, Lee CR, Brown D, Xu P, Man S, Jayaraman L, Rohde E, Chow A, Lazarus D, Eliasof S, Foster FS, Kerbel RS. Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle-drug conjugate, in treatment of metastatic triple-negative breast cancer. Cancer Research. PMID 27325647 DOI: 10.1158/0008-5472.CAN-15-3435  0.56
2015 Emmenegger U, Booth CM, Berry S, Sridhar SS, Winquist E, Bandali N, Chow A, Lee C, Xu P, Man S, Kerbel RS, Ko YJ. Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer. The Oncologist. PMID 26542984 DOI: 10.1634/theoncologist.2015-0220  0.56
2015 Paez-Ribes M, Man S, Xu P, Kerbel RS. Potential Pro-invasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26169967 DOI: 10.1158/1078-0432.CCR-15-0915  0.56
2015 Kuczynski EA, Lee CR, Man S, Chen E, Kerbel RS. Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. Cancer Research. 75: 2510-9. PMID 25908587 DOI: 10.1158/0008-5472.CAN-14-3687  0.56
2015 Jedeszko C, Paez-Ribes M, Di Desidero T, Man S, Lee CR, Xu P, Bjarnason GA, Bocci G, Kerbel RS. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Science Translational Medicine. 7: 282ra50. PMID 25855496 DOI: 10.1126/scitranslmed.3010722  0.56
2015 Wu FT, Lee CR, Bogdanovic E, Prodeus A, Gariépy J, Kerbel RS. Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2. Embo Molecular Medicine. 7: 770-87. PMID 25851538 DOI: 10.15252/emmm.201404193  0.56
2015 Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 808-18. PMID 25524310 DOI: 10.1158/1078-0432.CCR-14-2810  0.56
2015 Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM. PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2138-47. PMID 25316811 DOI: 10.1158/1078-0432.CCR-14-0861  0.56
2014 Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. Embo Molecular Medicine. 6: 1561-76. PMID 25361689 DOI: 10.15252/emmm.201403989  0.56
2014 Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, Curigliano G, Di Desidero T, Eniu A, Fazio N, Kerbel R, et al. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. Ecancermedicalscience. 8: 463. PMID 25228919 DOI: 10.3332/ecancer.2014.463  0.56
2014 Buckstein R, Kerbel R, Cheung M, Shaked Y, Chodirker L, Lee CR, Lenis M, Davidson C, Cussen MA, Reis M, Chesney A, Zhang L, Mamedov A, Wells RA. Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. Leukemia Research. 38: 756-63. PMID 24819395 DOI: 10.1016/j.leukres.2014.03.022  0.56
2014 Cruz-Muñoz W, Di Desidero T, Man S, Xu P, Jaramillo ML, Hashimoto K, Collins C, Banville M, O'Connor-McCourt MD, Kerbel RS. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis. 17: 661-73. PMID 24569856 DOI: 10.1007/s10456-014-9422-9  0.56
2014 Ardelean DS, Yin M, Jerkic M, Peter M, Ngan B, Kerbel RS, Foster FS, Letarte M. Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis. Angiogenesis. 17: 641-59. PMID 24510304 DOI: 10.1007/s10456-014-9421-x  0.56
2014 Ardelean DS, Jerkic M, Yin M, Peter M, Ngan B, Kerbel RS, Foster FS, Letarte M. Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment. Angiogenesis. 17: 129-46. PMID 24061911 DOI: 10.1007/s10456-013-9383-4  0.56
2014 Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy Investigational New Drugs. 32: 47-59. PMID 23728939 DOI: 10.1007/s10637-013-9974-3  0.56
2013 Di Desidero T, Fioravanti A, Orlandi P, Canu B, Giannini R, Borrelli N, Man S, Xu P, Fontanini G, Basolo F, Kerbel RS, Francia G, Danesi R, Bocci G. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. The Journal of Clinical Endocrinology and Metabolism. 98: E1465-73. PMID 23969186 DOI: 10.1210/jc.2013-1364  0.56
2013 Alkins R, Burgess A, Ganguly M, Francia G, Kerbel R, Wels WS, Hynynen K. Focused ultrasound delivers targeted immune cells to metastatic brain tumors. Cancer Research. 73: 1892-9. PMID 23302230 DOI: 10.1158/0008-5472.CAN-12-2609  0.56
2013 Todorova M, Agache V, Mortazavi O, Chen B, Karshafian R, Hynynen K, Man S, Kerbel RS, Goertz DE. Antitumor effects of combining metronomic chemotherapy with the antivascular action of ultrasound stimulated microbubbles. International Journal of Cancer. Journal International Du Cancer. 132: 2956-66. PMID 23225339 DOI: 10.1002/ijc.27977  0.56
2012 Cruz-Muñoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O'Connor-McCourt MD, Kerbel RS. Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Research. 72: 4909-19. PMID 22865454 DOI: 10.1158/0008-5472.CAN-12-2194  0.56
2012 Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, ... ... Kerbel RS, et al. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis. 15: 275-86. PMID 22382585 DOI: 10.1007/s10456-012-9260-6  0.56
2011 Cao Y, Arbiser J, D'Amato RJ, D'Amore PA, Ingber DE, Kerbel R, Klagsbrun M, Lim S, Moses MA, Zetter B, Dvorak H, Langer R. Forty-year journey of angiogenesis translational research. Science Translational Medicine. 3: 114rv3. PMID 22190240 DOI: 10.1126/scitranslmed.3003149  0.56
2011 Schmid MC, Avraamides CJ, Foubert P, Shaked Y, Kang SW, Kerbel RS, Varner JA. Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Research. 71: 6965-75. PMID 21948958 DOI: 10.1158/0008-5472.CAN-11-0588  0.56
2010 Langenberg MH, Nijkamp MW, Roodhart JM, Snoeren N, Tang T, Shaked Y, van Hillegersberg R, Witteveen PO, Vermaat JS, Kranenburg O, Kerbel RS, Medema RH, Borel Rinkes IH, Voest EE. Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF. Cancer Biology & Therapy. 9: 743-8. PMID 20215863 DOI: 10.4161/cbt.9.9.11551  0.56
2010 Mamluk R, Carvajal IM, Morse BA, Wong H, Abramowitz J, Aslanian S, Lim AC, Gokemeijer J, Storek MJ, Lee J, Gosselin M, Wright MC, Camphausen RT, Wang J, Chen Y, ... ... Kerbel R, et al. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. Mabs. 2: 199-208. PMID 20190562 DOI: 10.4161/mabs.2.2.11304  0.56
2010 Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 723-30. PMID 20026801 DOI: 10.1200/JCO.2009.24.0143  0.56
2010 Shaked Y, Nathan P, Daenen LGM, Kerbel RS. Combining antiangiogenic drugs with vascular disrupting agents rationale and mechanisms of action Vascular Disruptive Agents For the Treatment of Cancer. 117-134. DOI: 10.1007/978-1-4419-6609-4_6  0.56
2009 Francia G, Man S, Lee CJ, Lee CR, Xu P, Mossoba ME, Emmenegger U, Medin JA, Kerbel RS. Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6358-66. PMID 19825954 DOI: 10.1158/1078-0432.CCR-09-0931  0.56
2009 Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM, Chaplin DJ, Kerbel RS. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Molecular Cancer Therapeutics. 8: 2872-81. PMID 19825805 DOI: 10.1158/1535-7163.MCT-09-0583  0.56
2009 Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, Cai SR, Arbeit JM, Voest EE, Chaplin DJ, Smythe J, Harris A, Nathan P, Judson I, Rustin G, ... ... Kerbel RS, et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Research. 69: 7524-8. PMID 19738066 DOI: 10.1158/0008-5472.CAN-09-0381  0.56
2009 Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, Wong JW, Kerbel RS, O'Malley FP, Andrulis IL, Wrana JL. A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America. 106: 14028-33. PMID 19667198 DOI: 10.1073/pnas.0906796106  0.48
2009 Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proceedings of the National Academy of Sciences of the United States of America. 106: 3794-9. PMID 19234131 DOI: 10.1073/pnas.0804543106  0.48
2008 Francia G, Emmenegger U, Lee CR, Shaked Y, Folkins C, Mossoba M, Medin JA, Man S, Zhu Z, Witte L, Kerbel RS. Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Molecular Cancer Therapeutics. 7: 3452-9. PMID 18852148 DOI: 10.1158/1535-7163.MCT-08-0200  0.56
2008 Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, ... ... Kerbel RS, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 14: 263-73. PMID 18772115 DOI: 10.1016/j.ccr.2008.08.001  0.56
2008 Voskas D, Babichev Y, Ling LS, Alami J, Shaked Y, Kerbel RS, Ciruna B, Dumont DJ. An eosinophil immune response characterizes the inflammatory skin disease observed in Tie-2 transgenic mice. Journal of Leukocyte Biology. 84: 59-67. PMID 18443190 DOI: 10.1189/jlb.0607347  0.56
2008 Doñate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2137-44. PMID 18381955 DOI: 10.1158/1078-0432.CCR-07-4530  0.56
2008 Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Research. 68: 521-9. PMID 18199548 DOI: 10.1158/0008-5472.CAN-07-3217  0.48
2007 Rychak JJ, Graba J, Cheung AM, Mystry BS, Lindner JR, Kerbel RS, Foster FS. Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Molecular Imaging. 6: 289-96. PMID 18092513 DOI: 10.2310/7290.2007.00024  0.56
2007 Bosch-Marce M, Okuyama H, Wesley JB, Sarkar K, Kimura H, Liu YV, Zhang H, Strazza M, Rey S, Savino L, Zhou YF, McDonald KR, Na Y, Vandiver S, Rabi A, ... ... Kerbel R, et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circulation Research. 101: 1310-8. PMID 17932327 DOI: 10.1161/CIRCRESAHA.107.153346  0.56
2007 Cervi D, Shaked Y, Haeri M, Usenko T, Lee CR, Haigh JJ, Nagy A, Kerbel RS, Yefenof E, Ben-David Y. Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia. Blood. 109: 2139-46. PMID 17053052 DOI: 10.1182/blood-2005-11-026823  0.36
2006 du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 904-16. PMID 16467105 DOI: 10.1158/1078-0432.CCR-05-1109  0.56
2005 Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 438: 967-74. PMID 16355214 DOI: 10.1038/nature04483  0.56
2005 Francia G, Green SK, Bocci G, Man S, Emmenegger U, Ebos JML, Weinerman A, Shaked Y, Kerbel RS. Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: Implications for multicellular resistance to alkylating agents Molecular Cancer Therapeutics. 4: 1484-1494. PMID 16227397 DOI: 10.1158/1535-7163.MCT-04-0214  0.56
2005 Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: A complementation antiangiogenic strategy Clinical Cancer Research. 11: 6678-6685. PMID 16166447 DOI: 10.1158/1078-0432.CCR-05-0621  0.56
2005 Liu Z, Li H, Derouet M, Filmus J, LaCasse EC, Korneluk RG, Kerbel RS, Rosen KV. ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. The Journal of Biological Chemistry. 280: 37383-92. PMID 16115895 DOI: 10.1074/jbc.M503724200  0.56
2005 Voskas D, Jones N, Van Slyke P, Sturk C, Chang W, Haninec A, Babichev YO, Tran J, Master Z, Chen S, Ward N, Cruz M, Jones J, Kerbel RS, Jothy S, et al. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. The American Journal of Pathology. 166: 843-55. PMID 15743796 DOI: 10.1016/S0002-9440(10)62305-X  0.56
2005 Shaked Y, Cervi D, Neuman M, Chen L, Klement G, Michaud CR, Haeri M, Pak BJ, Kerbel RS, Ben-David Y. The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells. Blood. 105: 4500-7. PMID 15701719 DOI: 10.1182/blood-2004-08-3210  0.56
2005 Davidoff AM, Ng CYC, Zhang Y, Streck CJ, Mabry SJ, Barton SH, Baudino T, Zhou J, Kerbel RS, Vanin EF, Nathwani AC. Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability Molecular Therapy. 11: 300-310. PMID 15668142 DOI: 10.1016/j.ymthe.2004.09.014  0.56
2005 Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, ... Kerbel RS, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell. 7: 101-11. PMID 15652753 DOI: 10.1016/j.ccr.2004.11.023  0.48
2004 Bocci G, Man S, Green SK, Francia G, Ebos JML, Du Manoir JM, Weinerman A, Emmenegger U, Ma L, Thorpe P, Davidoff A, Huber J, Hicklin DJ, Kerbel RS. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies Cancer Research. 64: 6616-6625. PMID 15374976 DOI: 10.1158/0008-5472.CAN-04-0401  0.56
2004 Vande Woude GF, Kelloff GJ, Ruddon RW, Koo HM, Sigman CC, Barrett JC, Day RW, Dicker AP, Kerbel RS, Parkinson DR, Slichenmyer WJ. Reanalysis of cancer drugs: old drugs, new tricks. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3897-907. PMID 15173099 DOI: 10.1158/1078-0432.CCR-03-0786  0.56
2004 Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3881-4. PMID 15173097 DOI: 10.1158/1078-0432.CCR-03-0783  0.56
2004 Viloria-Petit AM, Kerbel RS. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. International Journal of Radiation Oncology, Biology, Physics. 58: 914-26. PMID 14967451 DOI: 10.1016/j.ijrobp.2003.09.091  0.48
2004 Pak BJ, Lee J, Thai BL, Fuchs SY, Shaked Y, Ronai Z, Kerbel RS, Ben-David Y. Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. Oncogene. 23: 30-8. PMID 14712208 DOI: 10.1038/sj.onc.1207007  0.56
2003 Gesundheit B, Klement G, Senger C, Kerbel R, Kieran M, Baruchel S, Becker L. Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood. Medical and Pediatric Oncology. 41: 516-26. PMID 14595708 DOI: 10.1002/mpo.10308  0.56
2003 Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. The Embo Journal. 22: 4091-102. PMID 12912908 DOI: 10.1093/emboj/cdg408  0.56
2003 Master Z, Tran J, Bishnoi A, Chen SH, Ebos JM, Van Slyke P, Kerbel RS, Dumont DJ. Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization. The Journal of Biological Chemistry. 278: 30170-9. PMID 12777393 DOI: 10.1074/jbc.M301339200  0.48
2003 Jones N, Chen SH, Sturk C, Master Z, Tran J, Kerbel RS, Dumont DJ. A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Molecular and Cellular Biology. 23: 2658-68. PMID 12665569  0.48
2003 Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS. High-frequency 3-D color-flow imaging of the microcirculation. Ultrasound in Medicine & Biology. 29: 39-51. PMID 12604116 DOI: 10.1016/s0301-5629(02)00682-8  0.56
2002 Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E, Kerbel RS. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Molecular Cancer Research : McR. 1: 89-95. PMID 12496355  0.48
2002 Yu JL, Coomber BL, Kerbel RS. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation; Research in Biological Diversity. 70: 599-609. PMID 12492501 DOI: 10.1046/j.1432-0436.2002.700913.x  0.56
2002 Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS. High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Research. 62: 6371-5. PMID 12438217  0.56
2002 Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Research. 62: 1931-4. PMID 11929804  0.56
2002 Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proceedings of the National Academy of Sciences of the United States of America. 99: 4349-54. PMID 11917134 DOI: 10.1073/pnas.072586399  0.56
2002 Yu JL, Rak JW, Klement G, Kerbel RS. Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Research. 62: 1838-46. PMID 11912163  0.56
2002 Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 13: 12-5. PMID 11863092 DOI: 10.1093/annonc/mdf093  0.56
2002 Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science (New York, N.Y.). 295: 1526-8. PMID 11859195 DOI: 10.1126/science.1068327  0.56
2001 Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Reviews. 20: 79-86. PMID 11831651 DOI: 10.1023/A:1013172910858  0.56
2001 Pak BJ, Chu W, Lu SJ, Kerbel RS, Ben-David Y. Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein 2. Cancer Metastasis Reviews. 20: 27-32. PMID 11831643 DOI: 10.1023/A:1013175516793  0.56
2001 Master Z, Jones N, Tran J, Jones J, Kerbel RS, Dumont DJ. Dok-R plays a pivotal role in angiopoietin-1-dependent cell migration through recruitment and activation of Pak. The Embo Journal. 20: 5919-28. PMID 11689432 DOI: 10.1093/emboj/20.21.5919  0.48
2001 Mayer B, Klement G, Kaneko M, Man S, Jothy S, Rak J, Kerbel RS. Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. Gastroenterology. 121: 839-52. PMID 11606498 DOI: 10.1053/GAST.2001.27989  0.56
2001 Frankel A, Rosen K, Filmus J, Kerbel RS. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L). Cancer Research. 61: 4837-41. PMID 11406560  0.6
2001 Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL. Heterogeneous vascular dependence of tumor cell populations. The American Journal of Pathology. 158: 1325-34. PMID 11290550 DOI: 10.1016/S0002-9440(10)64083-7  0.56
2000 Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. The Journal of Investigative Dermatology. Symposium Proceedings / the Society For Investigative Dermatology, Inc. [and] European Society For Dermatological Research. 5: 24-33. PMID 11147671 DOI: 10.1046/j.1087-0024.2000.00012.x  0.56
2000 Pak BJ, Li Q, Kerbel RS, Ben-David Y. TYRP2-mediated resistance to cis-diamminedichloroplatinum (II) in human melanoma cells is independent of tyrosinase and TYRP1 expression and melanin content. Melanoma Research. 10: 499-505. PMID 11095412 DOI: 10.1097/00008390-200010000-00013  0.56
2000 Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 3719-28. PMID 10999766  0.6
2000 Kerbel RS, Viloria-Petit A, Klement G, Rak J. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. European Journal of Cancer (Oxford, England : 1990). 36: 1248-57. PMID 10882863 DOI: 10.1016/S0959-8049(00)00092-7  0.56
2000 Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. The Journal of Clinical Investigation. 105: R15-24. PMID 10772661 DOI: 10.1172/JCI8829  0.56
2000 Rosen K, Rak J, Leung T, Dean NM, Kerbel RS, Filmus J. Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. The Journal of Cell Biology. 149: 447-56. PMID 10769035 DOI: 10.1083/jcb.149.2.447  0.48
2000 Goertz DE, Christopher DA, Yu JL, Kerbel RS, Burns PN, Foster FS. High-frequency color flow imaging of the microcirculation. Ultrasound in Medicine & Biology. 26: 63-71. PMID 10687794  0.56
2000 Chu W, Pak BJ, Bani MR, Kapoor M, Lu SJ, Tamir A, Kerbel RS, Ben-David Y. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogene. 19: 395-402. PMID 10656687 DOI: 10.1038/sj.onc.1203315  0.56
1999 Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG, Kerbel RS. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochemical and Biophysical Research Communications. 264: 781-8. PMID 10544009 DOI: 10.1006/bbrc.1999.1589  0.56
1999 Green SK, Frankel A, Kerbel RS. Adhesion-dependent multicellular drug resistance. Anti-Cancer Drug Design. 14: 153-68. PMID 10405642  0.56
1999 Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21(WAF1/CIP1) is lost during progression of human malignant melanoma Oncogene. 18: 1023-1032. PMID 10023678 DOI: 10.1038/sj.onc.1202382  0.56
1998 Bayko L, Rak J, Man S, Bicknell R, Ferrara N, Kerbel RS. The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. Angiogenesis. 2: 203-17. PMID 14517461 DOI: 10.1023/A:1009275307663  0.48
1998 Rosen K, Rak J, Jin J, Kerbel RS, Newman MJ, Filmus J. Downregulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells. Current Biology : Cb. 8: 1331-4. PMID 9843689 DOI: 10.1016/S0960-9822(07)00564-7  0.48
1998 St. Croix B, Sheehan C, Rak JW, Fłorenes VA, Slingerland JM, Kerbel RS. E-cadherin-dependent growth suppression is mediated by the cyclin- dependent kinase inhibitor p27(KIP1) Journal of Cell Biology. 142: 557-571. PMID 9679152 DOI: 10.1083/jcb.142.2.557  0.56
1998 Flørenes VA, Mælandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p27(Kip1) in malignant melanoma: Inverse correlation with disease-free survival American Journal of Pathology. 153: 305-312. PMID 9665492  0.56
1997 Frankel A, Buckman R, Kerbel RS. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Research. 57: 2388-93. PMID 9192815  0.6
1996 St. Croix B, Flørenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS. Impact of the cyclin-dependent kinase inhibitor p27(Kip1) on resistance of tumor cells to anticancer agents Nature Medicine. 2: 1204-1210. PMID 8898746 DOI: 10.1038/nm1196-1204  0.56
1996 Croix BS, Rak JW, Kapitain S, Sheehan C, Graham CH, Kerbel RS. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. Journal of the National Cancer Institute. 88: 1285-96. PMID 8797768  0.56
1995 Rak J, Mitsuhashi Y, Erdos V, Huang SN, Filmus J, Kerbel RS. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. The Journal of Cell Biology. 131: 1587-98. PMID 8522614 DOI: 10.1083/jcb.131.6.1587  0.48
1995 Paglia D, Oran A, Lu C, Kerbel RS, Sauder DN, McKenzie RC. Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated Journal of Interferon and Cytokine Research. 15: 455-460. PMID 7648448 DOI: 10.1089/jir.1995.15.455  0.56
1994 Graham CH, Kobayashi H, Stankiewicz KS, Man S, Kapitain SJ, Kerbel RS. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents Journal of the National Cancer Institute. 86: 975-982. PMID 8007019 DOI: 10.1093/jnci/86.13.975  0.56
1994 Kerbel RS, Kobayashi H, Graham CH. Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes? Journal of Cellular Biochemistry. 56: 37-47. PMID 7806590  0.56
1994 Kerbel RS, Rak J, Kobayashi H, Man MS, St. Croix B, Graham CH. Multicellular resistance: A new paradigm to explain aspects of acquired drug resistance of solid tumors Cold Spring Harbor Symposia On Quantitative Biology. 59: 661-672. PMID 7587127  0.56
1993 Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS. Acquired multicellular-mediated resistance to alkylating agents in cancer Proceedings of the National Academy of Sciences of the United States of America. 90: 3294-3298. PMID 8475071  0.56
1993 Graham CH, Hawley TS, Hawley RG, Macdougall JR, Kerbel RS, Khoo N, Lala PK. Establishment and characterization of first trimester human trophoblast cells with extended lifespan Experimental Cell Research. 206: 204-211. PMID 7684692  0.56
1992 Wu S, Theodorescu D, Kerbel RS, Willson JKV, Mulder KM, Humphrey LE, Brattain MG. TGF-βi is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector Journal of Cell Biology. 116: 187-196. PMID 1730743 DOI: 10.1083/jcb.116.1.187  0.56
1991 Menter DG, Patton JT, Updyke TV, Kerbel RS, Maamer M, Mcintire LV, Nicolson GL. Transglutaminase stabilizes melanoma adhesion under laminar flow Cell Biophysics. 18: 123-143. PMID 1726525 DOI: 10.1007/BF02989810  0.56
1991 Graham GM, Guarini L, Moulton TA, Datta S, Ferrone S, Giacomini P, Kerbel RS, Fisher PB. Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons. Cancer Immunology, Immunotherapy : Cii. 32: 382-90. PMID 1672507 DOI: 10.1007/BF01741333  0.56
1989 Yagel S, Khokha R, Denhardt DT, Kerbel RS, Parhar RS, Lala PK. Mechanisms of cellular invasiveness: A comparison of amnion invasion in vitro and metastatic behavior in vivo Journal of the National Cancer Institute. 81: 768-775. PMID 2541259 DOI: 10.1093/jnci/81.10.768  0.56
1984 Lagarde AE, Donaghue TP, Kerbel R, Siminovitch L. Metastatic properties of distinct phenotypic classes of lectin-resistant mutants isolated from murine MDAY-D2 cell line. Somatic Cell and Molecular Genetics. 10: 503-19. PMID 6591445 DOI: 10.1007/BF01534855  0.56
1981 Dennis J, Donaghue T, Florian M, Kerbel RS. Apparent reversion of stable in vitro genetic markers detected in tumour cells from spontaneous metastases Nature. 292: 242-245. PMID 6894784 DOI: 10.1038/292242a0  0.56
1980 Kerbel RS, McKenzie IFC, Florian M, Man MS, Dennis J. Carcinogenicity of tumor cell populations: Origin of a putative h-2 isoantigenic loss variant tumor Journal of the National Cancer Institute. 64: 1221-1230. PMID 6929020 DOI: 10.1093/jnci/64.5.1221  0.56
Show low-probability matches.